文献速递胸部病理细胞病理与分子病理

非小细胞肺癌细胞学样本PD-L1检测与配对穿刺活检的一致性

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
PubMed 文献 · Cancer Cytopathol · 2018-03-02

本研究评估非小细胞肺癌细针穿刺细胞学样本(直接涂片和细胞块)PD-L1免疫组化检测与配对空芯针活检的一致性。细胞块阴性9/10一致、阳性22/28一致,不一致可能与肿瘤异质性有关。

要点

  • 细胞学涂片和细胞块PD-L1检测与配对活检一致性高。
  • 涂片阴性9例全部与活检一致,阳性28例仅1例不一致。
  • 细胞块6例不一致,可能与肿瘤异质性有关。

核心结论

  • 非小细胞肺癌细胞学样本评估PD-L1与配对空芯针活检高度一致,可用于评估PD-L1表达。

研究设计与样本

  • 每例的巴氏染色直接涂片和细胞块切片均用Dako PD-L1 pharmDx抗体(克隆22C3)染色。
  • 仅评估肿瘤细胞≥100的切片,包括37张涂片和38个细胞块。
  • 根据肿瘤细胞部分/完全膜染色计算肿瘤比例评分(TPS),并与配对空芯针活检比较。

主要发现

  • 9张PD-L1阴性涂片与配对活检100%一致。
  • 28张PD-L1阳性涂片中,除1张不一致外,其余TPS与配对活检相似。
  • 10例配对活检阴性中,9个细胞块阴性一致,1个细胞块TPS为1%至5%。
  • 其余28个细胞块显示PD-L1表达,其中22例TPS与配对活检相似,6个细胞块不一致,可能因肿瘤异质性。

关键数值与推荐

  • 仅肿瘤细胞≥100的涂片(37张)和细胞块(38个)纳入评估。
  • PD-L1免疫组化使用Dako PD-L1 pharmDx抗体(克隆22C3)。
  • TPS基于肿瘤细胞部分/完全膜染色计算。

临床怎么用

  • 非小细胞肺癌细胞学样本(直接涂片和细胞块)可用于PD-L1免疫组化检测,与活检一致性高。
  • 判读时需确保肿瘤细胞数量≥100,并注意细胞块与活检不一致可能反映肿瘤异质性。

局限性

  • 细胞块不一致可能归因于肿瘤异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1) receptor and its ligand, programmed death ligand 1 (PD-L1), have emerged as a therapeutic approach for patients with non-small cell lung carcinoma (NSCLC). PD-L1 expression, assessed by immunohistochemistry (IHC), is used to select patients for PD-1/PD-L1 inhibitor therapy. Most studies have been performed with histology specimens, with limited data available on the performance in cytology specimens. This study evaluated PD-L1 in cytology specimens and compared the results with those from paired core-needle biopsy for concordance. METHODS: Forty-one NSCLC fine-needle aspiration cases that had paired core-needle biopsy specimens with PD-L1 IHC were selected. A Papanicolaou-stained direct smear and a cell block section from each case were stained with a Dako PD-L1 pharmDx antibody (clone 22C3). Only slides with 100 or more tumor cells (37 smears and 38 cell blocks) were evaluated. Tumor proportion scores (TPS) were assessed on the basis of the partial/complete membranous staining of tumor cells and were correlated with those of paired core-needle biopsy. RESULTS: All 9 smears that were negative for PD-L1 staining showed 100% concordance with the paired core-needle biopsy, whereas 28 smears with PD-L1 expression showed a similar TPS, except for 1 smear that was discordant. In contrast, 10 negative paired core-needle biopsy cases corresponded to 9 concordant negative cell blocks, whereas 1 cell block had a TPS of 1% to 5%. The remaining 28 cell blocks demonstrated PD-L1 expression, with 22 cases showing a TPS similar to that of the paired core-needle biopsy, whereas 6 cell blocks were discordant, likely because of intratumoral heterogeneity. CONCLUSIONS: The results show that NSCLC cytology samples evaluated for PD-L1 have high concordance with paired core-needle biopsy samples and can be used for assessing PD-L1 expression. Cancer Cytopathol 2018;126:342-52. © 2018 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Noll B, Wang WL, Gong Y, et al. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Cancer Cytopathol. 2018. PMID: 29499101. doi:10.1002/cncy.21987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。